Page 10 - GPD-4-3

Gene & Protein in Disease Circadian biology in Alzheimer’s disease

Chronotherapy – the alignment of medical treatment The phrase “time is brain,” often cited in stroke care, is
with biological rhythms – is a promising avenue for equally profound in the context of Alzheimer’s disease. It
Alzheimer’s disease care. Drug metabolism follows is time for temporal regulation to emerge as a therapeutic
circadian patterns, influencing efficacy and toxicity. target.
Melatonin, traditionally used to regulate sleep, also
influences autophagy, oxidative stress, and synaptic Conflict of interest
signaling – making it a promising chronotherapeutic The author declares no conflict of interest.
agent. In addition, dual orexin receptor antagonists have
shown early success in regulating sleep-wake cycles and References
promoting tau clearance. 9 1. Hippius H, Neundorfer G. The discovery of Alzheimer’s
Restoring circadian synchrony through lifestyle disease. Dialogues Clin Neurosci. 2003;5(1):101-108.
interventions – such as time-restricted feeding, structured doi: 10.31887/DCNS.2003.5.1/hhippius
light exposure, and regular physical activity – has shown 2. Korczyn AD, Grinberg LT. Is Alzheimer disease a disease?
benefits in sleep quality, systemic inflammation, and Nat Rev Neurol. 2024;20(4):245-251.
cognitive resilience, particularly in the early stages of
Alzheimer’s disease. 10 doi: 10.1038/s41582-024-00940-4
A growing field of interest is chronoepigenetics, where 3. Hoyt KR, Obrietan K. Circadian clocks, cognition, and
epigenetic regulators – such as sirtuin-1, an NAD - Alzheimer’s disease: Synaptic mechanisms, signaling
+
effectors, and chronotherapeutics. Mol Neurodegener.
dependent deacetylase, and poly(ADP-ribose) polymerase 2022;17(1):35.
1 – intersect with circadian clock gene expression,
modulating neuroprotective and synaptic pathways. 11,12 doi: 10.1186/s13024-022-00537-9
Targeting these molecular intersections may lead to 4. Gibson M. A systematic review of the relationship between
precision therapies that simultaneously stabilize circadian night shift work and oxidative stress. Chronobiol Int.
rhythms and mitigate neurodegeneration. 2022;39(2):285-298.
These insights also transform our approach to doi: 10.1080/07420528.2021.1989446
biomarkers. Circadian-informed markers – such as 5. Gonzales PNG, Villaraza SG, Rosa JCD. The association
rhythmic fluctuations in melatonin, cortisol, body between sleep and Alzheimer’s disease: A systematic review.
temperature, retinal responses, and microglial activation – Dement Neuropsychol. 2024;18:e20230049.
may offer early diagnostic signals and optimize therapeutic doi: 10.1590/1980-5764-DN-2023-0049
timing. Technologies such as actigraphy, metabolomic
profiling, and neuroimaging of circadian structures are 6. Morrone CD, Raghuraman R, Hussaini SA, Yu WH.
Proteostasis failure exacerbates neuronal circuit dysfunction
advancing the field of time-based phenotyping and risk and sleep impairments in Alzheimer’s disease. Mol
stratification. Neurodegener. 2023;18(1):27.

Despite these advances, challenges remain. Clinical doi: 10.1186/s13024-023-00617-4
adoption of chronotherapy is hindered by the absence of 7. Son G, Neylan TC, Grinberg LT. Neuronal and glial
standardized chronotyping protocols, limited longitudinal vulnerability of the suprachiasmatic nucleus in tauopathies:
data, and the lack of circadian integration into trial design. Evidence from human studies and animal models. Mol
Regulatory frameworks must evolve to incorporate time- Neurodegener. 2024;19(1):4.
of-day considerations in drug labeling and approval. Public
health initiatives should also promote circadian hygiene doi: 10.1186/s13024-023-00695-4
– including consistent sleep schedules, timed meals, and 8. Mueed Z, Rai PK, Kamal MA, Poddar NK. Decoding the
light exposure – as a core component of brain health. inter-relationship between sleep disorders and Alzheimer’s
disease pathogenesis. CNS Neurol Disord Drug Targets.
As Alzheimer’s disease cases continue to rise globally, 2021;20(8):723-735.
particularly among aging and urbanized populations,
there is an urgent need to expand our clinical and research doi: 10.2174/1871527319666200903161249
frameworks. The circadian system, once considered 9. Carpi M, Mercuri NB, Liguori C. Orexin receptor antagonists
peripheral, now emerges as a central regulatory axis linking for the prevention and treatment of Alzheimer’s disease and
genes, proteins, metabolism, and behavior within a unified associated sleep disorders. Drugs. 2024;84(11):1365-1378.
pathophysiological model. doi: 10.1007/s40265-024-02096-3

Volume 4 Issue 3 (2025) 2 doi: 10.36922/GPD025160031